Pfizer Inc.
DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCER
Last updated:
Abstract:
The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
9 Feb 2022
Issue date:
14 Jul 2022